nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—migraine—Prednisone—chronic obstructive pulmonary disease	0.658	1	CpDpCtD
Dihydroergotamine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0327	0.215	CbGbCtD
Dihydroergotamine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0221	0.145	CbGbCtD
Dihydroergotamine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0211	0.139	CbGbCtD
Dihydroergotamine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0188	0.124	CbGbCtD
Dihydroergotamine—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0184	0.121	CbGbCtD
Dihydroergotamine—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0174	0.114	CbGbCtD
Dihydroergotamine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.011	0.0726	CbGbCtD
Dihydroergotamine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0104	0.0685	CbGbCtD
Dihydroergotamine—Ergotamine—CYP1A2—chronic obstructive pulmonary disease	0.000831	0.276	CrCbGaD
Dihydroergotamine—Bromocriptine—CYP1A2—chronic obstructive pulmonary disease	0.000801	0.266	CrCbGaD
Dihydroergotamine—Ergotamine—HTR2A—chronic obstructive pulmonary disease	0.000701	0.233	CrCbGaD
Dihydroergotamine—Bromocriptine—HTR2A—chronic obstructive pulmonary disease	0.000676	0.225	CrCbGaD
Dihydroergotamine—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000358	0.00242	CcSEcCtD
Dihydroergotamine—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000358	0.00242	CcSEcCtD
Dihydroergotamine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000355	0.0024	CcSEcCtD
Dihydroergotamine—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000351	0.00238	CcSEcCtD
Dihydroergotamine—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.00035	0.00237	CcSEcCtD
Dihydroergotamine—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000349	0.00236	CcSEcCtD
Dihydroergotamine—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000349	0.00236	CcSEcCtD
Dihydroergotamine—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000347	0.00235	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000345	0.00234	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000345	0.00234	CcSEcCtD
Dihydroergotamine—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000345	0.00233	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000343	0.00232	CcSEcCtD
Dihydroergotamine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000342	0.00231	CcSEcCtD
Dihydroergotamine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000342	0.00231	CcSEcCtD
Dihydroergotamine—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000341	0.00231	CcSEcCtD
Dihydroergotamine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000341	0.00231	CcSEcCtD
Dihydroergotamine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.00034	0.0023	CcSEcCtD
Dihydroergotamine—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000338	0.00229	CcSEcCtD
Dihydroergotamine—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000338	0.00229	CcSEcCtD
Dihydroergotamine—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000336	0.00227	CcSEcCtD
Dihydroergotamine—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000336	0.00227	CcSEcCtD
Dihydroergotamine—Hiccups—Prednisone—chronic obstructive pulmonary disease	0.000335	0.00227	CcSEcCtD
Dihydroergotamine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000335	0.00227	CcSEcCtD
Dihydroergotamine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000331	0.00224	CcSEcCtD
Dihydroergotamine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000329	0.00223	CcSEcCtD
Dihydroergotamine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000329	0.00222	CcSEcCtD
Dihydroergotamine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000329	0.00222	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000326	0.00221	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000326	0.00221	CcSEcCtD
Dihydroergotamine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000323	0.00218	CcSEcCtD
Dihydroergotamine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000322	0.00218	CcSEcCtD
Dihydroergotamine—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000321	0.00217	CcSEcCtD
Dihydroergotamine—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000321	0.00217	CcSEcCtD
Dihydroergotamine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000317	0.00214	CcSEcCtD
Dihydroergotamine—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000317	0.00214	CcSEcCtD
Dihydroergotamine—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000317	0.00214	CcSEcCtD
Dihydroergotamine—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000317	0.00214	CcSEcCtD
Dihydroergotamine—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000317	0.00214	CcSEcCtD
Dihydroergotamine—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000317	0.00214	CcSEcCtD
Dihydroergotamine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000316	0.00214	CcSEcCtD
Dihydroergotamine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000316	0.00214	CcSEcCtD
Dihydroergotamine—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000316	0.00214	CcSEcCtD
Dihydroergotamine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000315	0.00213	CcSEcCtD
Dihydroergotamine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000315	0.00213	CcSEcCtD
Dihydroergotamine—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000313	0.00212	CcSEcCtD
Dihydroergotamine—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000313	0.00212	CcSEcCtD
Dihydroergotamine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.00031	0.0021	CcSEcCtD
Dihydroergotamine—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.00031	0.0021	CcSEcCtD
Dihydroergotamine—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.00031	0.0021	CcSEcCtD
Dihydroergotamine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00031	0.0021	CcSEcCtD
Dihydroergotamine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00031	0.0021	CcSEcCtD
Dihydroergotamine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000309	0.00209	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000308	0.00208	CcSEcCtD
Dihydroergotamine—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000304	0.00205	CcSEcCtD
Dihydroergotamine—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000304	0.00205	CcSEcCtD
Dihydroergotamine—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000303	0.00205	CcSEcCtD
Dihydroergotamine—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000299	0.00202	CcSEcCtD
Dihydroergotamine—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000299	0.00202	CcSEcCtD
Dihydroergotamine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000299	0.00202	CcSEcCtD
Dihydroergotamine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000298	0.00202	CcSEcCtD
Dihydroergotamine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000297	0.00201	CcSEcCtD
Dihydroergotamine—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000297	0.00201	CcSEcCtD
Dihydroergotamine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000296	0.00201	CcSEcCtD
Dihydroergotamine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000296	0.00201	CcSEcCtD
Dihydroergotamine—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000295	0.002	CcSEcCtD
Dihydroergotamine—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000295	0.002	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000294	0.00199	CcSEcCtD
Dihydroergotamine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000292	0.00198	CcSEcCtD
Dihydroergotamine—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000292	0.00198	CcSEcCtD
Dihydroergotamine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000288	0.00195	CcSEcCtD
Dihydroergotamine—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000287	0.00194	CcSEcCtD
Dihydroergotamine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000284	0.00192	CcSEcCtD
Dihydroergotamine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000284	0.00192	CcSEcCtD
Dihydroergotamine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000282	0.00191	CcSEcCtD
Dihydroergotamine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.00191	CcSEcCtD
Dihydroergotamine—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000282	0.00191	CcSEcCtD
Dihydroergotamine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.00028	0.00189	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000277	0.00188	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000277	0.00188	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000277	0.00187	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000277	0.00187	CcSEcCtD
Dihydroergotamine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000275	0.00186	CcSEcCtD
Dihydroergotamine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000275	0.00186	CcSEcCtD
Dihydroergotamine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000273	0.00185	CcSEcCtD
Dihydroergotamine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000273	0.00185	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000271	0.00183	CcSEcCtD
Dihydroergotamine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000271	0.00183	CcSEcCtD
Dihydroergotamine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000271	0.00183	CcSEcCtD
Dihydroergotamine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00027	0.00183	CcSEcCtD
Dihydroergotamine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00027	0.00183	CcSEcCtD
Dihydroergotamine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000269	0.00182	CcSEcCtD
Dihydroergotamine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000268	0.00181	CcSEcCtD
Dihydroergotamine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000267	0.00181	CcSEcCtD
Dihydroergotamine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000267	0.00181	CcSEcCtD
Dihydroergotamine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000267	0.00181	CcSEcCtD
Dihydroergotamine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000266	0.0018	CcSEcCtD
Dihydroergotamine—Injury—Prednisone—chronic obstructive pulmonary disease	0.000265	0.00179	CcSEcCtD
Dihydroergotamine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00179	CcSEcCtD
Dihydroergotamine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000264	0.00179	CcSEcCtD
Dihydroergotamine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000262	0.00177	CcSEcCtD
Dihydroergotamine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000262	0.00177	CcSEcCtD
Dihydroergotamine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000262	0.00177	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.00177	CcSEcCtD
Dihydroergotamine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00026	0.00176	CcSEcCtD
Dihydroergotamine—Pain—Formoterol—chronic obstructive pulmonary disease	0.00026	0.00176	CcSEcCtD
Dihydroergotamine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000259	0.00175	CcSEcCtD
Dihydroergotamine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000257	0.00174	CcSEcCtD
Dihydroergotamine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000256	0.00174	CcSEcCtD
Dihydroergotamine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00173	CcSEcCtD
Dihydroergotamine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.00172	CcSEcCtD
Dihydroergotamine—Pain—Montelukast—chronic obstructive pulmonary disease	0.000254	0.00172	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000254	0.00172	CcSEcCtD
Dihydroergotamine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000254	0.00172	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000253	0.00171	CcSEcCtD
Dihydroergotamine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000252	0.00171	CcSEcCtD
Dihydroergotamine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000252	0.0017	CcSEcCtD
Dihydroergotamine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000251	0.0017	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000251	0.0017	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.00025	0.00169	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.00025	0.00169	CcSEcCtD
Dihydroergotamine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00025	0.00169	CcSEcCtD
Dihydroergotamine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000249	0.00169	CcSEcCtD
Dihydroergotamine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000249	0.00168	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000248	0.00168	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000248	0.00168	CcSEcCtD
Dihydroergotamine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000247	0.00167	CcSEcCtD
Dihydroergotamine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000245	0.00166	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000243	0.00165	CcSEcCtD
Dihydroergotamine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000241	0.00163	CcSEcCtD
Dihydroergotamine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000241	0.00163	CcSEcCtD
Dihydroergotamine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00024	0.00162	CcSEcCtD
Dihydroergotamine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.00024	0.00162	CcSEcCtD
Dihydroergotamine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00024	0.00162	CcSEcCtD
Dihydroergotamine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.00024	0.00162	CcSEcCtD
Dihydroergotamine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000239	0.00162	CcSEcCtD
Dihydroergotamine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000237	0.00161	CcSEcCtD
Dihydroergotamine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000237	0.0016	CcSEcCtD
Dihydroergotamine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000237	0.0016	CcSEcCtD
Dihydroergotamine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000236	0.0016	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.0016	CcSEcCtD
Dihydroergotamine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000236	0.0016	CcSEcCtD
Dihydroergotamine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000235	0.00159	CcSEcCtD
Dihydroergotamine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000235	0.00159	CcSEcCtD
Dihydroergotamine—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000235	0.00159	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000234	0.00159	CcSEcCtD
Dihydroergotamine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000228	0.00154	CcSEcCtD
Dihydroergotamine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000227	0.00153	CcSEcCtD
Dihydroergotamine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000227	0.00153	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000224	0.00151	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000224	0.00151	CcSEcCtD
Dihydroergotamine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000223	0.00151	CcSEcCtD
Dihydroergotamine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000223	0.00151	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000219	0.00148	CcSEcCtD
Dihydroergotamine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000218	0.00147	CcSEcCtD
Dihydroergotamine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000218	0.00147	CcSEcCtD
Dihydroergotamine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000215	0.00145	CcSEcCtD
Dihydroergotamine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000215	0.00145	CcSEcCtD
Dihydroergotamine—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000214	0.00145	CcSEcCtD
Dihydroergotamine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000213	0.00144	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00143	CcSEcCtD
Dihydroergotamine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00021	0.00142	CcSEcCtD
Dihydroergotamine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000208	0.00141	CcSEcCtD
Dihydroergotamine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000208	0.00141	CcSEcCtD
Dihydroergotamine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000206	0.00139	CcSEcCtD
Dihydroergotamine—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000205	0.00139	CcSEcCtD
Dihydroergotamine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000203	0.00138	CcSEcCtD
Dihydroergotamine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.00137	CcSEcCtD
Dihydroergotamine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000201	0.00136	CcSEcCtD
Dihydroergotamine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000201	0.00136	CcSEcCtD
Dihydroergotamine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000197	0.00133	CcSEcCtD
Dihydroergotamine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000196	0.00133	CcSEcCtD
Dihydroergotamine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000193	0.00131	CcSEcCtD
Dihydroergotamine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000193	0.00131	CcSEcCtD
Dihydroergotamine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000191	0.0013	CcSEcCtD
Dihydroergotamine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000191	0.0013	CcSEcCtD
Dihydroergotamine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000191	0.00129	CcSEcCtD
Dihydroergotamine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000191	0.00129	CcSEcCtD
Dihydroergotamine—Headache—Formoterol—chronic obstructive pulmonary disease	0.00019	0.00129	CcSEcCtD
Dihydroergotamine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.00129	CcSEcCtD
Dihydroergotamine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00019	0.00128	CcSEcCtD
Dihydroergotamine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000189	0.00128	CcSEcCtD
Dihydroergotamine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000188	0.00127	CcSEcCtD
Dihydroergotamine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000187	0.00127	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000187	0.00127	CcSEcCtD
Dihydroergotamine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000186	0.00126	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000185	0.00125	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000184	0.00124	CcSEcCtD
Dihydroergotamine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000182	0.00123	CcSEcCtD
Dihydroergotamine—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000182	0.00123	CcSEcCtD
Dihydroergotamine—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000181	0.00123	CcSEcCtD
Dihydroergotamine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.00122	CcSEcCtD
Dihydroergotamine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.00122	CcSEcCtD
Dihydroergotamine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00018	0.00122	CcSEcCtD
Dihydroergotamine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00018	0.00122	CcSEcCtD
Dihydroergotamine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00018	0.00122	CcSEcCtD
Dihydroergotamine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000177	0.0012	CcSEcCtD
Dihydroergotamine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000174	0.00118	CcSEcCtD
Dihydroergotamine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00115	CcSEcCtD
Dihydroergotamine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000169	0.00115	CcSEcCtD
Dihydroergotamine—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000164	0.00111	CcSEcCtD
Dihydroergotamine—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.00109	CcSEcCtD
Dihydroergotamine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.00016	0.00109	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000159	0.00108	CcSEcCtD
Dihydroergotamine—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000156	0.00106	CcSEcCtD
Dihydroergotamine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000149	0.00101	CcSEcCtD
Dihydroergotamine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000999	CcSEcCtD
Dihydroergotamine—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000141	0.000952	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000919	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000136	0.000917	CcSEcCtD
Dihydroergotamine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000911	CcSEcCtD
Dihydroergotamine—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000894	CcSEcCtD
Dihydroergotamine—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000132	0.00089	CcSEcCtD
Dihydroergotamine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000131	0.000884	CcSEcCtD
Dihydroergotamine—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000855	CcSEcCtD
Dihydroergotamine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000125	0.000844	CcSEcCtD
Dihydroergotamine—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000125	0.000844	CcSEcCtD
Dihydroergotamine—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000841	CcSEcCtD
Dihydroergotamine—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000833	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000121	0.00082	CcSEcCtD
Dihydroergotamine—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000809	CcSEcCtD
Dihydroergotamine—Shock—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000796	CcSEcCtD
Dihydroergotamine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000789	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000782	CcSEcCtD
Dihydroergotamine—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000771	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000737	CcSEcCtD
Dihydroergotamine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000109	0.000736	CcSEcCtD
Dihydroergotamine—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000731	CcSEcCtD
Dihydroergotamine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000726	CcSEcCtD
Dihydroergotamine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000712	CcSEcCtD
Dihydroergotamine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000703	CcSEcCtD
Dihydroergotamine—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.000702	CcSEcCtD
Dihydroergotamine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.000701	CcSEcCtD
Dihydroergotamine—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000697	CcSEcCtD
Dihydroergotamine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000697	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	9.85e-05	0.000666	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	9.77e-05	0.000661	CcSEcCtD
Dihydroergotamine—Nausea—Prednisolone—chronic obstructive pulmonary disease	9.77e-05	0.000661	CcSEcCtD
Dihydroergotamine—Urticaria—Prednisone—chronic obstructive pulmonary disease	9.49e-05	0.000642	CcSEcCtD
Dihydroergotamine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	9.45e-05	0.000639	CcSEcCtD
Dihydroergotamine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	9.45e-05	0.000639	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	8.8e-05	0.000596	CcSEcCtD
Dihydroergotamine—Asthenia—Prednisone—chronic obstructive pulmonary disease	8.57e-05	0.00058	CcSEcCtD
Dihydroergotamine—Pruritus—Prednisone—chronic obstructive pulmonary disease	8.45e-05	0.000572	CcSEcCtD
Dihydroergotamine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	8.18e-05	0.000553	CcSEcCtD
Dihydroergotamine—Dizziness—Prednisone—chronic obstructive pulmonary disease	7.9e-05	0.000535	CcSEcCtD
Dihydroergotamine—Vomiting—Prednisone—chronic obstructive pulmonary disease	7.6e-05	0.000514	CcSEcCtD
Dihydroergotamine—Rash—Prednisone—chronic obstructive pulmonary disease	7.53e-05	0.00051	CcSEcCtD
Dihydroergotamine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	7.53e-05	0.000509	CcSEcCtD
Dihydroergotamine—Headache—Prednisone—chronic obstructive pulmonary disease	7.49e-05	0.000507	CcSEcCtD
Dihydroergotamine—Nausea—Prednisone—chronic obstructive pulmonary disease	7.1e-05	0.00048	CcSEcCtD
Dihydroergotamine—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	3.71e-05	0.000934	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	3.7e-05	0.000933	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	3.69e-05	0.000931	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.66e-05	0.000923	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.63e-05	0.000916	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.57e-05	0.000899	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.56e-05	0.000897	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.54e-05	0.000893	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—PLAUR—chronic obstructive pulmonary disease	3.54e-05	0.000893	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GC—chronic obstructive pulmonary disease	3.47e-05	0.000874	CbGpPWpGaD
Dihydroergotamine—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	3.46e-05	0.000872	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.39e-05	0.000856	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.37e-05	0.000849	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.34e-05	0.000842	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.32e-05	0.000838	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.3e-05	0.000831	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.27e-05	0.000825	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.27e-05	0.000825	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.25e-05	0.000818	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.23e-05	0.000814	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.23e-05	0.000813	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.22e-05	0.000813	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.18e-05	0.000801	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.13e-05	0.000789	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.13e-05	0.000789	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.11e-05	0.000783	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.1e-05	0.000783	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.08e-05	0.000777	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.04e-05	0.000767	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.04e-05	0.000767	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.04e-05	0.000766	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.03e-05	0.000765	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.01e-05	0.000758	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	3.01e-05	0.000758	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.99e-05	0.000753	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	2.98e-05	0.000752	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.98e-05	0.000751	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.97e-05	0.000749	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.97e-05	0.000747	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.95e-05	0.000743	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	2.95e-05	0.000743	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.89e-05	0.000728	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.87e-05	0.000725	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.86e-05	0.000721	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.86e-05	0.00072	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.86e-05	0.00072	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.85e-05	0.000718	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	2.84e-05	0.000717	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.84e-05	0.000716	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.81e-05	0.000709	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.78e-05	0.000701	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.71e-05	0.000683	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.71e-05	0.000683	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.61e-05	0.000658	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.6e-05	0.000655	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.58e-05	0.00065	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	2.56e-05	0.000646	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—MMP1—chronic obstructive pulmonary disease	2.53e-05	0.000638	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.53e-05	0.000636	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—PLAU—chronic obstructive pulmonary disease	2.48e-05	0.000626	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.47e-05	0.000621	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.46e-05	0.00062	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.42e-05	0.00061	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	2.4e-05	0.000605	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.39e-05	0.000602	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.37e-05	0.000598	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	2.35e-05	0.000593	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.32e-05	0.000584	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.32e-05	0.000584	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.29e-05	0.000578	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.29e-05	0.000577	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—NOS2—chronic obstructive pulmonary disease	2.28e-05	0.000575	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.27e-05	0.000573	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.26e-05	0.000569	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.23e-05	0.000562	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.22e-05	0.000561	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.2e-05	0.000554	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.13e-05	0.000537	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.13e-05	0.000536	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.12e-05	0.000534	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.11e-05	0.000532	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.09e-05	0.000527	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.07e-05	0.000521	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.99e-05	0.000502	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.96e-05	0.000495	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.95e-05	0.000491	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.94e-05	0.00049	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.93e-05	0.000487	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.92e-05	0.000485	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	1.92e-05	0.000484	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—ALB—chronic obstructive pulmonary disease	1.92e-05	0.000483	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.91e-05	0.000482	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.91e-05	0.000481	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.9e-05	0.00048	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.89e-05	0.000478	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GCLC—chronic obstructive pulmonary disease	1.87e-05	0.000472	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—NOS3—chronic obstructive pulmonary disease	1.83e-05	0.000462	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.83e-05	0.000461	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.82e-05	0.000459	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.82e-05	0.000459	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.79e-05	0.000452	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.79e-05	0.000452	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.77e-05	0.000446	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.75e-05	0.000442	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.75e-05	0.000442	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.74e-05	0.000439	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.73e-05	0.000436	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.72e-05	0.000433	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CTGF—chronic obstructive pulmonary disease	1.71e-05	0.000431	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.71e-05	0.000431	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.71e-05	0.00043	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.69e-05	0.000427	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.66e-05	0.00042	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.61e-05	0.000407	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.61e-05	0.000405	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.6e-05	0.000404	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.59e-05	0.000402	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.59e-05	0.000402	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.58e-05	0.000399	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.57e-05	0.000397	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.57e-05	0.000397	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.56e-05	0.000393	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.55e-05	0.000391	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.54e-05	0.000387	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.52e-05	0.000384	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.52e-05	0.000383	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.51e-05	0.000381	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.51e-05	0.00038	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.49e-05	0.000376	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.48e-05	0.000372	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.47e-05	0.000369	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.46e-05	0.000367	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.45e-05	0.000366	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.43e-05	0.00036	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.42e-05	0.000357	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.4e-05	0.000353	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.39e-05	0.00035	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.37e-05	0.000346	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.33e-05	0.000336	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.32e-05	0.000333	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.31e-05	0.000331	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.31e-05	0.00033	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.31e-05	0.00033	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.3e-05	0.000328	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.3e-05	0.000327	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.3e-05	0.000326	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.3e-05	0.000326	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.24e-05	0.000312	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.21e-05	0.000306	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.21e-05	0.000304	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.19e-05	0.0003	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.18e-05	0.000298	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.18e-05	0.000298	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.17e-05	0.000296	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.16e-05	0.000294	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.15e-05	0.000289	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.14e-05	0.000288	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.14e-05	0.000288	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.14e-05	0.000287	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.14e-05	0.000286	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.12e-05	0.000282	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.11e-05	0.00028	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.09e-05	0.000274	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.09e-05	0.000274	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.07e-05	0.00027	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.07e-05	0.000269	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.06e-05	0.000267	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.06e-05	0.000266	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.04e-05	0.000262	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.03e-05	0.000259	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.02e-05	0.000258	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.02e-05	0.000257	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TP53—chronic obstructive pulmonary disease	9.99e-06	0.000252	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.76e-06	0.000246	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.48e-06	0.000239	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.41e-06	0.000237	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.34e-06	0.000235	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.28e-06	0.000234	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.22e-06	0.000232	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.08e-06	0.000229	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.02e-06	0.000227	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.96e-06	0.000226	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.95e-06	0.000226	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.93e-06	0.000225	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.76e-06	0.000221	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	8.69e-06	0.000219	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.66e-06	0.000218	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.58e-06	0.000216	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.51e-06	0.000215	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.35e-06	0.00021	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.34e-06	0.00021	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.3e-06	0.000209	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.29e-06	0.000209	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.23e-06	0.000207	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.07e-06	0.000203	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	7.98e-06	0.000201	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.91e-06	0.000199	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.91e-06	0.000199	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.83e-06	0.000197	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—chronic obstructive pulmonary disease	7.78e-06	0.000196	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.7e-06	0.000194	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.64e-06	0.000193	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.48e-06	0.000189	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—NOS3—chronic obstructive pulmonary disease	7.44e-06	0.000188	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	7.28e-06	0.000184	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.07e-06	0.000178	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.03e-06	0.000177	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.02e-06	0.000177	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.02e-06	0.000177	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.93e-06	0.000175	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.88e-06	0.000173	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.87e-06	0.000173	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.83e-06	0.000172	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.74e-06	0.00017	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.71e-06	0.000169	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.68e-06	0.000168	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.52e-06	0.000164	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.45e-06	0.000163	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.35e-06	0.00016	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.33e-06	0.000159	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.22e-06	0.000157	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.82e-06	0.000147	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.78e-06	0.000146	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.7e-06	0.000144	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.66e-06	0.000143	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.59e-06	0.000141	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.52e-06	0.000139	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.52e-06	0.000139	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	5.38e-06	0.000136	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.33e-06	0.000134	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.31e-06	0.000134	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.29e-06	0.000133	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.25e-06	0.000132	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.23e-06	0.000132	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.18e-06	0.00013	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	5.14e-06	0.00013	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.14e-06	0.00013	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.13e-06	0.000129	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.99e-06	0.000126	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.87e-06	0.000123	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.86e-06	0.000123	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.48e-06	0.000113	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.31e-06	0.000109	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.11e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.03e-06	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.94e-06	9.94e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.39e-06	8.53e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.31e-06	8.35e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.17e-06	7.99e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.1e-06	7.81e-05	CbGpPWpGaD
